Literature DB >> 1956401

Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.

P A Roche1, M S Marks, P Cresswell.   

Abstract

HLA class II molecules are heterodimeric transmembrane glycoproteins that bind and present processed antigenic peptides to CD4-positive T lymphocytes. Intracellularly, class II molecules associate with a third subunit termed the invariant (I) chain. Here we describe the physical characteristics of the intracellular class II alpha beta I complex. Chemical crosslinking, size exclusion chromatography and sedimentation velocity studies demonstrate that the alpha beta I complex is a nine-subunit transmembrane protein that contains three alpha beta dimers associated with an I chain trimer. The organization of class II alpha- and beta-subunits in such a multimer may have a role in the documented ability of the I chain to inhibit peptide binding to class II molecules. In addition, the formation of the nine-chain complex may induce the structural changes necessary to overcome the cytoplasmic retention signal responsible for the localization of free I chain in the endoplasmic reticulum, releasing class II-I chain complexes for transport to endosomes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1956401     DOI: 10.1038/354392a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  90 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

2.  Interaction of human immunodeficiency virus type 2 Vpx and invariant chain.

Authors:  H A Pancio; N Vander Heyden; K Kosuri; P Cresswell; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Regulation of intracellular trafficking of human CD1d by association with MHC class II molecules.

Authors:  Suk-Jo Kang; Peter Cresswell
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

4.  DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.

Authors:  Cornelia H Rinderknecht; Sujin Roh; Achal Pashine; Michael P Belmares; Namrata S Patil; Ning Lu; Phi Truong; Tieying Hou; Claudia Macaubas; Taejin Yoon; Nan Wang; Robert Busch; Elizabeth D Mellins
Journal:  Immunology       Date:  2010-04-12       Impact factor: 7.397

5.  The immune function of MHC class II molecules mutated in the putative superdimer interface.

Authors:  John D Hayball; Richard A Lake
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

6.  Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii.

Authors:  A Jasanoff; G Wagner; D C Wiley
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

7.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.

Authors:  Kaoru Saegusa; Naozumi Ishimaru; Kumiko Yanagi; Rieko Arakaki; Kouichi Ogawa; Ichiro Saito; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 8.  The biological function and significance of CD74 in immune diseases.

Authors:  Huiting Su; Ning Na; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2016-10-17       Impact factor: 4.575

9.  Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

Authors:  S Demotz; W Ammerlaan; P Fournier; C P Muller; C Barbey
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.